7 results
Stroke and bleeding risk stratification with the CHADS2-VASc and HAS-BLED schemas

#Diagnosis #Hematology #CHADS2 #CHADS2VASc #HASBLED #Comparison
Stroke and bleeding ... HAS-BLED schemas #Diagnosis ... #Hematology #CHADS2 ... #CHADS2VASc #HASBLED ... Stroke #Bleed #Anticoagulation
Bleeding risk calculators - HAS-BLED (atrial fibrillation) and IMPROVE (VTE prophylaxis for inpatients)
Important notes:
 • No
Bleeding risk calculators ... risk #HASBLED ... Calculators #Anticoagulation ... #Factors #Hematology ... #Diagnosis
Treatment algorithm for VTE in Malignancy

(A) Suggested treatment algorithm for symptomatic and incidental DVT or PE
and incidental DVT ... without concomitant DVT ... #Anticoagulation ... #Management #Hematology ... #Oncology
CHA2DS2VASc vs HAS-BLED scores for stroke risk and bleed risk on anticoagulation

C	Congestive Heart Failure	1

H	Hypertension	1

A2	Age >75	2

D	Diabetes Mellitus	1

S2	Stroke,
on anticoagulation ... S Stroke 1 B Bleeding ... CHADS2 #CHADS2VASc #HASBLED ... #AFib #Diagnosis ... #Hematology
Patient risk stratification algorithm for the treatment of cancer-associated thrombosis.

Currently, edoxaban and rivaroxaban are the only
Patient risk stratification ... DVT = deep vein ... #Anticoagulation ... #Management #Hematology ... #Oncology
Longterm Venous Thromboembolism Treatment Algorithm
Treat for 3 months and reassess
 • Isolated distal DVT (without cancer)
Isolated distal DVT ... Unprovoked proximal DVT ... PE - High Bleeding ... #management #hematology ... #anticoagulation
Essential Thrombocythemia (ET)
ET is a chronic myeloproliferative neoplasm. Most cases are related to mutations that affect
MI, stroke, DVT/ ... • Treatment algorithms ... patients with no CV risk ... Hydroxyurea + anticoagulation ... #hematology